Helix BioPharma Corp.
🇩🇪XFRA.HBP0GermanyHealthcare
Price€0.54-0.02 (-3.57%)
Latest anomalies
Very negative 45 detected in the last 120 days
- High: 2
- Medium: 40
- Low: 2
12-1M momentum: flipped sign, from negative to positive
Overnight gap: a gap down from the prior close
Overnight gap: a gap down from the prior close
Overnight gap: a gap down from the prior close
12-1M momentum: flipped sign, from negative to positive
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Germany
Identity
- Exchange
- Frankfurt Stock Exchange . XFRA
- Type
- Stock
- ISIN
- CA4229102088
- CUSIP
- Not reported
Company
- Employees
- 7
- Headquarters
- Vancouver, Canada
Market
- Shares outstanding
- 76.4M
- Market cap
- €52.14M
Key dates
- Next earnings
- Oct 29, 2026
Highlights
- Market cap
- €52.14M
- EPS LTM
- -CA$0.12calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$00%unchanged year on year
- Net income
- -CA$9.53M-55.24%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$3.93M+34.69%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Helix BioPharma Corp. is a company in the healthcare sector, listed on Frankfurt Stock Exchange (Germany) under the ticker HBP0. Its market capitalisation is €52.14M, from 76.4M shares outstanding, as of . Across the 252 trading sessions to the shares traded between €0.39 and €3.56, and the last close of €0.54 sits 5% of the way up that range. The company is headquartered in Vancouver, Canada, and employs about 7 people. This is the Frankfurt Stock Exchange listing of Helix BioPharma Corp.; its primary listing is HBP on Toronto Stock Exchange.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.